New Biotech ElevateBio Brings In $150M From Investors
A group of investors led by private equity-backed UBS Oncology Impact Fund and F2 Ventures on Monday agreed to inject $150 million into ElevateBio, a newly launched biotech focused on building...To view the full article, register now.
Already a subscriber? Click here to view full article